Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Symbicort was produced by AstraZeneca and Astellas.

AZ's Symbicort suffers setback

AstraZeneca has been denied approval by the FDA for the use of its asthma drug Symbicort in children aged 6-11 years old. ... Symbicort was approved in the US for use in children over 12 years old for long-term maintenance of asthma in July 2009.

The PM Society Advertising Awards 2008

Highly commended: Zonegran by Big Pink for Eisai Ltd. Winner: Symbicort Smart.

PMEA 2008: Results and winners and pictures

by Pfizer.                                                                                  . Highly Commended. Symbicort SMART Launch. by AstraZeneca in association

Symbicort patent loss drags down AZ's share value

Symbicort racked up FY06 global sales of USD 1.2bn. The EU region accounted for USD 1bn of total sales. ... They also reduced estimates of Symbicort's 2012 sales in the EU region from USD 1.7bn to USD 599m.

Pharma news in brief

The US Food and Drug Administration (FDA) has approved AstraZeneca's (AZ) inhaled asthma drug, Symbicort, for the long-term treatment of patients aged 12 or over - a year earlier than ... AZ plans to market Symbicort in the US in mid-2007. Shares in AZ

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...